Hiring among CLO tranche investors in Europe has picked up this year, and the profile firms want has moved with it.
At Laz Partners we are seeing credit funds scope dedicated tranche seats, usually at senior analyst level with room to move towards PM or trading. Accounts that only bought US CLOs are building European coverage for relative value.
The job behind those seats is different. For years, buying CLO paper meant allocating to the asset class. Increasingly it means choosing between managers and reading the documents.
Allocators we speak to describe BB as equity-like risk in a market where single-name dispersion is rising. Managers themselves expect the spread gap between stronger and weaker platforms to keep widening, most of all in BBB and below. Relative value between managers is now the trade.
The buyers are changing: Solvency II capital charges on senior CLO tranches fall sharply for EU insurers from 30th January, 2027, bringing more insurance capital into the senior stack. US managers keep opening European platforms, which gives tranche buyers more managers to choose between, and more ways to get it wrong.
The arbitrage is thinner: With roughly half of the loans CLOs favour priced above par, and repricings squeezing asset spreads, managers have less room for error. The return for a tranche investor has to come from somewhere else. Mostly, it comes from manager selection and structure.
That changes who gets hired.
The scarce profile sits close to execution: someone who can screen bonds quickly, set one manager’s portfolio against another’s and hold their own in a negotiation. The analysis that counts centres on the weakest name in each portfolio, and on structure and documentation, with less weight on single-name loan work. Looser covenants and PIK features are eroding collateral quality, and the person who catches that in the documents before it reaches the ratings is hard to find.
Capacity is thin. We know of a team of seven covering around 40 names.
